Hillgene
Research - Suzhou, Jiangsu, China
Hillgene Employees
Hillgene Details
PXBio is positioned as a leading cell drug CDMO company. Its shareholders include the National Small and Medium-sized Enterprise Development Fund, the Chinese Academy of Sciences Holding National Kejiahe Fund, Haier Capital, Winbond Health, and China CITIC Construction Investment Fund. The company is headquartered in the beautiful Taihu Lake-Wuzhong District, Suzhou City, with a registered capital of 100 million yuan. It has a Suzhou headquarters (10000m2GMP plant) and a Shenzhen base (8000m2GMP plant under construction). It has initially formed a nationwide production base network layout; North America The card base is also under construction, and the global production capacity layout is simultaneously carried out. PXBio focuses on the field of cell therapy drugs, and has built a special plasmid construction platform for cell drugs, a suspension serum-free virus production platform and a fully enclosed cell process development platform, creating a highway from discovery to product delivery. The platform has supported multiple partners to successfully incubate multiple CAR-T, TCR-T, stem cell and other drugs. Committed to making more projects reach the next milestone sooner and faster, bringing more cell drugs to the market, benefiting more patients, and allowing cell drugs to write a new chapter in life.
